Related Experiment Videos
Polynitroxylated starch/TPL attenuates cachexia and increased epithelial permeability associated with TNBS colitis
1Department of Molecular and Cellular Physiology, Louisiana State University Health and Sciences Center, Shreveport 71130, USA.
Inflammation
|April 9, 2002
Summary
Polynitroxyl starch plus Tempol (PNS/TPL) demonstrates antioxidant effects, reducing inflammation and improving outcomes in a colitis model. This novel compound may offer a new therapy for inflammatory bowel disease (IBD) by inhibiting leukocyte adhesion and endothelial cell injury.
Area of Science:
- Biomedical Science
- Pharmacology
- Gastroenterology
Background:
- Free radicals contribute to inflammatory bowel disease (IBD) pathogenesis.
- Targeting oxidative stress presents a potential therapeutic strategy for IBD.
Purpose of the Study:
- To evaluate the antioxidant capacity and protective effects of polynitroxyl starch plus Tempol (PNS/TPL) in a colitis model.
- To investigate the efficacy of PNS/TPL in mitigating oxidant-induced inflammation and tissue damage.
Main Methods:
- In vitro assessment of superoxide scavenging capacity and inhibition of neutrophil-endothelial adhesion.
- In vivo evaluation in a mouse model of trinitrobenzene sulfonic acid (TNBS)-induced colitis.
- Measurement of body weight, survival rate, colonic mucosal damage, and intestinal permeability.
Main Results:
- PNS/TPL exhibited superoxide dismutase (SOD)-like activity.
- PNS/TPL significantly inhibited X/XO-induced neutrophil-endothelial adhesion in vitro.
- PNS/TPL treatment ameliorated TNBS-induced cachexia, mortality, and increased intestinal permeability in vivo.
Conclusions:
- PNS/TPL possesses significant antioxidant properties beneficial for IBD treatment.
- The compound effectively inhibits oxidant-mediated leukocyte adhesion and endothelial cell injury.
- PNS/TPL shows promise as a novel therapeutic agent for inflammatory bowel disease.